ZA200605302B - Use of pentadienoic acid derivatives for the treatment of hyperuricemia - Google Patents

Use of pentadienoic acid derivatives for the treatment of hyperuricemia

Info

Publication number
ZA200605302B
ZA200605302B ZA200605302A ZA200605302A ZA200605302B ZA 200605302 B ZA200605302 B ZA 200605302B ZA 200605302 A ZA200605302 A ZA 200605302A ZA 200605302 A ZA200605302 A ZA 200605302A ZA 200605302 B ZA200605302 B ZA 200605302B
Authority
ZA
South Africa
Prior art keywords
hyperuricemia
treatment
acid derivatives
pentadienoic acid
pentadienoic
Prior art date
Application number
ZA200605302A
Other languages
English (en)
Inventor
Boizel Robert
Guerrier Daniel
Brutzkus Bertrand
Fouqueray Pascale
Zeiller Jean-Jacques
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200605302B publication Critical patent/ZA200605302B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
ZA200605302A 2003-11-28 2006-06-27 Use of pentadienoic acid derivatives for the treatment of hyperuricemia ZA200605302B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03292973A EP1535612B1 (de) 2003-11-28 2003-11-28 Behandlung von Hyperurikämie

Publications (1)

Publication Number Publication Date
ZA200605302B true ZA200605302B (en) 2007-04-25

Family

ID=34443102

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200605302A ZA200605302B (en) 2003-11-28 2006-06-27 Use of pentadienoic acid derivatives for the treatment of hyperuricemia

Country Status (19)

Country Link
US (2) US20070099854A1 (de)
EP (2) EP1535612B1 (de)
JP (1) JP2007512267A (de)
KR (1) KR20060111541A (de)
CN (1) CN1886129A (de)
AR (1) AR046676A1 (de)
AT (2) ATE339200T1 (de)
AU (1) AU2004294686B2 (de)
BR (1) BRPI0417003A (de)
CA (1) CA2547543A1 (de)
CY (1) CY1105308T1 (de)
DE (2) DE60308390T2 (de)
DK (1) DK1535612T3 (de)
ES (2) ES2272926T3 (de)
PT (1) PT1535612E (de)
RU (1) RU2006122852A (de)
SI (1) SI1535612T1 (de)
WO (1) WO2005053676A1 (de)
ZA (1) ZA200605302B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7823417B2 (en) * 2005-11-04 2010-11-02 Ocv Intellectual Capital, Llc Method of manufacturing high performance glass fibers in a refractory lined melter and fiber formed thereby
CN103980267B (zh) * 2013-02-08 2018-02-06 镇江新元素医药科技有限公司 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787789B1 (fr) * 1998-12-29 2002-06-14 Lipha Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
AU2852100A (en) * 1999-01-19 2000-08-29 Tularik Inc. Methods of modulating uric acid levels
EP1277729A4 (de) * 2000-04-28 2005-05-11 Sankyo Co Ppar-g(g)-modulatoren
WO2002085123A1 (en) * 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

Also Published As

Publication number Publication date
DE602004007546D1 (de) 2007-08-23
JP2007512267A (ja) 2007-05-17
AR046676A1 (es) 2005-12-14
BRPI0417003A (pt) 2007-01-16
WO2005053676A1 (en) 2005-06-16
ATE339200T1 (de) 2006-10-15
KR20060111541A (ko) 2006-10-27
DK1535612T3 (da) 2007-02-12
AU2004294686A1 (en) 2005-06-16
PT1535612E (pt) 2006-12-29
AU2004294686B2 (en) 2010-07-15
EP1686983B1 (de) 2007-07-11
EP1686983A1 (de) 2006-08-09
ATE366570T1 (de) 2007-08-15
CA2547543A1 (en) 2005-06-16
ES2286692T3 (es) 2007-12-01
CY1105308T1 (el) 2010-03-03
DE60308390T2 (de) 2007-09-06
CN1886129A (zh) 2006-12-27
RU2006122852A (ru) 2008-01-10
DE602004007546T2 (de) 2008-01-31
SI1535612T1 (sl) 2006-12-31
EP1535612B1 (de) 2006-09-13
ES2272926T3 (es) 2007-05-01
DE60308390D1 (de) 2006-10-26
EP1535612A1 (de) 2005-06-01
US20070099854A1 (en) 2007-05-03
US20100160410A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
EP1643986A4 (de) Phenylcarboxylat-beta-secretase-hemmer zur behandlung von morbus alzheimer
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
AP2006003671A0 (en) Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
EP1515725A4 (de) Verwendung von cyclothiocarbamat-derivativen bei der behandlung von hormonabhängigen erkrankungen
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
SI1487828T1 (sl) Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
PL1959957T3 (pl) Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości
EP1651237A4 (de) Verfahren zur behandlung von dermatologischen erkrankungen
EP1750698A4 (de) Für die behandlung von diabetes geeignete 5-anilino-4-heteroarylpyrazol-derivate
IL172126A0 (en) Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection
TWI350753B (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain
PL378212A1 (pl) Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy
PL381612A1 (pl) Pirydynowe pochodne alkilooksindoli jako aktywne czynniki 5-HT7
ZA200605302B (en) Use of pentadienoic acid derivatives for the treatment of hyperuricemia
HK1080369A1 (zh) 用於治療多發性骨髓瘤的埃博霉素衍生物
HK1087027A1 (en) Use of 2H-Ä1, 3Ü-oxazinoÄ3,2-AÜindole derivatives for the treatment of neuropathic pain
PL1620085T3 (pl) Zastosowanie pochodnych kwasu fenoksyoctowego do leczenia pęcherza nadreaktywnego
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
GB0312840D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases